THE FDA/CMS SUMMIT IS PARTNERING WITH PHARMA INTELLIGENCE’S THE PINK SHEET
new connections in 2018 and beyond
We’re thrilled to announce that the FDA/CMS Summit is partnering with Pharma Intelligence’s The Pink Sheet to drive the agenda for this year’s event. The Pink Sheet’s in-depth research, expert insight, and vast network of trusted experts will be leveraged in the FDA/CMS Summit program to deliver more value than ever before. This partnership will bring you new faces, emerging content, fresh perspectives, and more.
Get the latest information from the FDA on advanced therapeutics, the Overhaul of the New Drug Review Program, Post-Market Surveillance updates, and much more.
- Hear the regulatory focus Post Mid-Term Elections
- Understand the Biosimilar Action Plan
- Examine The Path Forward for Real-World Evidence
Hear directly from CDER on goals, trends, new drug development and approvals, & other CDER, CMS, FDA initiatives and developments for 2018 and beyond.
- FDA Priorities, policy, and changes in policy in regards to the biopharma industry
- CMS updates on changes to policy and new policies regarding biopharma
- Reauthorizing legislation, new and existing review, biosimilar competition and applications
Who is Pink Sheet?
Pink Sheet is the world’s premier source of policy and regulatory insights and analysis that impact strategic business decisions. Pink Sheet arms biopharma decision-makers around the globe with forward-looking implications and the context of policies, perspectives from insiders and thought-leaders, tracking of key data to inform policy or enforcement trends, and analysis of developments throughout the industry.
Chairperson: Nielsen Hobbes - Editor, The Pink Sheet
M. Nielsen Hobbs has more than 20 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining the “The Pink Sheet” he worked for Congressional Quarterly. Hobbs enjoys discussing BB-8 almost as much as he enjoys talking about 351(k).